| Not Yet Recruiting | Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment NCT07393555 | SWOG Cancer Research Network | Phase 2 |
| Not Yet Recruiting | SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer NCT07322341 | University of Washington | Phase 2 |
| Recruiting | MOv19-BBz CAR T Cells in FRa+ Cancers NCT07116057 | University of Pennsylvania | Phase 1 |
| Recruiting | Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cance NCT06616584 | SWOG Cancer Research Network | Phase 2 / Phase 3 |
| Recruiting | Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer NCT06616623 | Dwight Owen | Phase 1 |
| Recruiting | Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Exp NCT06031688 | SWOG Cancer Research Network | Phase 2 |
| Recruiting | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642 | Mayo Clinic | — |
| Not Yet Recruiting | Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Ce NCT06067776 | Jonathan Riess | Phase 1 |
| Withdrawn | OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cance NCT05935774 | University of Washington | Phase 2 |
| Recruiting | Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Ch NCT05642572 | SWOG Cancer Research Network | Phase 2 |
| Recruiting | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924 | Institut de Recherches Internationales Servier | Phase 1 / Phase 2 |
| Recruiting | SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Ca NCT05570825 | University of Washington | Phase 2 |
| Active Not Recruiting | Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer NCT05633602 | SWOG Cancer Research Network | Phase 3 |
| Recruiting | PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer NCT05234307 | Dwight Owen | Phase 1 |
| Withdrawn | Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer NCT05364645 | SWOG Cancer Research Network | Phase 2 |
| Active Not Recruiting | Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small C NCT05334329 | University of California, Irvine | Phase 1 |
| Recruiting | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positiv NCT05098210 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual NCT05096663 | SWOG Cancer Research Network | Phase 2 / Phase 3 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lu NCT04919369 | Dwight Owen | Phase 1 |
| Active Not Recruiting | Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Pos NCT04837716 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Pro NCT05022394 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer NCT04505267 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 7 NCT04533451 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Active Not Recruiting | Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-s NCT04250545 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Muta NCT04479306 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Can NCT04120454 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standa NCT04092283 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) NCT04268550 | SWOG Cancer Research Network | Phase 2 |
| Active Not Recruiting | Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCL NCT04227028 | City of Hope Medical Center | Phase 1 |
| Suspended | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients NCT03987555 | Wake Forest University Health Sciences | — |
| Recruiting | PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung C NCT04151940 | University of Washington | N/A |
| Completed | Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-smal NCT03971474 | SWOG Cancer Research Network | Phase 2 |
| Completed | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent NCT03845296 | SWOG Cancer Research Network | Phase 2 |
| Completed | Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell L NCT03581487 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung NCT03707938 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lun NCT03600701 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change NCT03191149 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic NCT03225664 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Can NCT03410043 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-sma NCT03132532 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurre NCT03110978 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizuma NCT03050060 | University of Washington | Phase 2 |
| Active Not Recruiting | Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) M NCT02503722 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC NCT03066206 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell NCT02642042 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Ca NCT02496663 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant No NCT02535338 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell NCT01912625 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in T NCT01708954 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Pre NCT01725165 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-I NCT01629498 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer NCT01281124 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metas NCT01217411 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Ca NCT00254384 | M.D. Anderson Cancer Center | Phase 1 |